CTRI/2012/10/003071进行中（未招募）3 期
A multi-center, open, uncontrolled phase 3 study to investigate the efficacy and safety of a 4-phasic oral contraceptive SH T00658ID containingestradiol valerate and dienogest in a 28-day regimen for 13 cycles in healthyfemale subjects
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 940
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Signed and dated informed consent, either by the subject or impartial witness, in case the subject is temporarily not able to sign, e.g., due to a broken hand.15
- •2. Healthy female subject requesting contraception.
- •3. Age between 18 and 40 years (inclusive). Smokers must not be older than 35 years at the time of informed consent.
- •4. Normal or clinically insignificant cervical smear not requiring further follow-up (a cervical smear must be obtained at the screening visit or a normal result must be documented within the previous 6 months). Human papilloma virus (HPV) testing in subjects with atypical cells of undetermined significance (ASCUS) may be used as an adjunctive test. Subjects with ASCUS may be included if they are negative for high-risk HPV strains.16
- •5. History of regular cyclic menstrual periods without hormonal contraceptive use
排除标准
- •1. Pregnancy or lactation (less than three months since delivery, abortion, or lactation
- •before start of treatment)
- •2. Body mass index17 (BMI) 32 kg/m2
- •3. Hypersensitivity to any ingredient of the study drug
- •4. Laboratory values outside inclusion range before allocation of treatment
- •5. Any disease or condition that can compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study medication (such as but not limited to duodenal ulcers,gastritis, gastrectomy or gastric resection surgery, or renal compromise)
- •6. Any disease or condition that might interfere with the conduct of the study or the interpretation of the results
- •7. Any disease or condition that may worsen under hormonal treatment according to the assessment and opinion of the investigator. The following are examples of such conditions or diseases:
- •Cardiovascular
- •- presence or a history of venous or arterial thrombotic / thromboembolic events (e.g.,
- •deep venous thrombosis, pulmonary embolism, myocardial infarction) or of a
- •cerebrovascular accident, including prodromi (e.g., transient ischemic attack, angina
- •pectoris) and conditions which could increase the risk of suffering from any of the
- •above mentioned disorders, e.g., a family history indicating a hereditary predisposition
- •- repeated measurements of systolic blood pressure 140 mmHg and/or diastolic blood
- •pressure 90 mmHg
- •- presence or history of liver tumors (benign or malignant)
- •- presence or history of severe hepatic disease, where liver function parameter values
- •have not returned to normal
- •- jaundice and / or pruritus related to cholestasis (except Gilbertâ??s syndrome)
- •- history of cholestatic jaundice associated with pregnancy or previous COC use
- •Metabolic diseases
- •- uncontrolled diabetes mellitus and/or diabetes mellitus with vascular involvement
- •- severe dyslipoproteinemia
- •Other diseases
- •- malignant or premalignant disease
- •- uncontrolled thyroid disorder
- •- chronic inflammatory bowel disease
- •- severe renal insufficiency or acute renal failure
- •- hemolytic uremic syndrome
- •- sickle cell anemia
- •- porphyria
- •- history of hypertriglyceridemia-associated pancreatitis
- •- systemic lupus erythematosus, pemphigoid gestationis during a previous pregnancy
- •- Sydenham chorea
- •- history of herpes gestationis
- •- otosclerosis-related hearing loss
- •- history of migraine with focal neurologic symptoms
- •- epilepsy
- •- clinically significant depression
- •- hereditary angioedema
- •8. Undiagnosed abnormal genital bleeding
- •9. Abuse of alcohol, drugs, or medicines (e.g., laxatives)
- •10. Other contraceptive methods:
- •- sterilization
- •- long-acting preparations (e.g., depot- medroxyprogesterone acetate, monthly
- •contraceptive injection) within a period of 3 times of the injection interval before start
- •of treatment. The use of non-study oral, vaginal, or transdermal hormonal
- •contraception, intrauterine devices (IUDs) with or without hormonal release, and
- •implants (still in place within 30 days of Visit 1) are prohibited during tr
研究者
相似试验
进行中（未招募）
不适用
A phase III, open, multi-centre, controlled study to evaluate the long-term antibody persistence at 2 years, 3 years and 4 years after a single dose of GlaxoSmithKline (GSK) Biologicals’ meningococcal serogroup A, C, W-135, Y- tetanus toxoid conjugate (MenACWY-TT) vaccine versus one dose of Meningitec™ administered in healthy 12 through 23-month old children who were primed in study MenACWY-TT-039 (109670) and to evaluate the immunogenicity and safety of a booster dose of the same meningococcal conjugate vaccine as given in the primary study, 4 years after priming. - MENACWY-TT-048 EXT:039 Y2, 3, 4, 5EUCTR2008-003824-51-FIGlaxoSmithKline Biologicals992
进行中（未招募）
1 期
Persistence of antibodies after meningococcal vaccine PF-06866681 in healthy children.EUCTR2012-005816-25-FIPfizer Inc (235 East 42nd Street, New York, New York 10017)248
进行中（未招募）
不适用
eo-Adjuvant Trial Add-OPatients with histological tumor residuals after preoperative anthracycline and taxane containing chemotherapy for primary breast cancerEUCTR2004-002355-14-ATGBG Forschungsgesellschaft mbH654
进行中（未招募）
不适用
A randomized, multicenter, open phase III study comparing the postoperative use of zoledronic acid versus no treatment in patients with histological tumor residuals after preoperative anthracycline and taxane containing chemotherapy for primary breast cancer (NEO-ADJUVANT TRIAL ADD-ON) - NATAPatients with histological tumor residuals after preoperative anthracycline and taxane containing chemotherapy for primary breast cancerEUCTR2004-002355-14-DEGBG Forschungsgesellschaft mbH654
进行中（未招募）
1 期
Immunogenicity and safety study of GlaxoSmithKline (GSK) Biologicals’ Boostrix™ vaccine and the Chinese DT vaccine, when administered as booster vaccination in healthy children aged 6-8 years.Healthy volunteers (Immunisation against diphtheria, tetanus and pertussis)MedDRA version: 19.0Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-000644-34-Outside-EU/EEAGlaxoSmithKline Biologicals660